2022
Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”
Yeong J, Teo C, Tay R, Tan B, Chan Y, Smyth E, Sundar R. Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”. Gastric Cancer 2022, 25: 1133-1135. PMID: 36152122, DOI: 10.1007/s10120-022-01343-4.Peer-Reviewed Original Research
2020
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
Sundar R, Smyth E, Peng S, Yeong J, Tan P. Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. Frontiers In Oncology 2020, 10: 763. PMID: 32500029, PMCID: PMC7243739, DOI: 10.3389/fonc.2020.00763.Peer-Reviewed Educational MaterialsImmune checkpoint inhibitionGastroesophageal cancerPredictive biomarkersCheckpoint inhibitionRandomized phase III studyImmune checkpoint inhibitor trialsValidation of predictive biomarkersCheckpoint inhibitor trialsPhase III studySubgroup of patientsIII studiesSurvival benefitInhibitor trialsPatient selectionGastroesophagealNovel biomarkersPrecision oncologyCancer treatmentCancerRegulatory approvalImmunotherapyNegative resultsBiomarkersPatientsInhibition
2016
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins D, Sundar R, Lim J, Yap T. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends In Pharmacological Sciences 2016, 38: 25-40. PMID: 27871777, DOI: 10.1016/j.tips.2016.10.012.Peer-Reviewed Educational MaterialsConceptsPrecision medicineNext-generation sequencingMechanisms of drug resistanceField of immunotherapyManagement of cancer patientsOptimize treatment efficacyAntitumor responseIntertumoral heterogeneityClonal evolutionTargeted agentsMinimal toxicityDrug resistanceCancer patientsTreatment efficacyBiomarker developmentBiomarker discoveryCancer researchCancerCompounds promisesImmunotherapyMedicine